SavedAdd your journal

Journals / Turkish Journal of Chemistry / 2005 / Cilt: 29 - Sayı: 2

Synthesis and Antimicrobial Evaluation of Some New 2-(2-(p-chlorophenyl) benzimidazol-1-yl methyl)-5-substituted amino-[1,3,4]-thiadiazoles

Gülgün AYHAN KILCIGİL
Canan KUŞ
Pages
153–162
Publication Date
2005-02-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Single crystal X-ray diffraction analysis was performed for compound 8b.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Some 2-(2-(p-chlorophenyl)benzimidazol-1-ylmethyl)-5-substituted amino-[1,3,4]-thiadiazoles were synthesized and their in vitro antimicrobial activities were tested against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Candida albicans and Candida krusei.
📊
Key Findings & Data:Compounds 1b and 12b which possess remarkable activity against C. albicans and marginal activity against C. krusei were found to be the most active compounds in this series.
💡
Conclusion & Impact:Single crystal X-ray diffraction analysis was performed for compound 8b.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Benzimidazoles · thiadiazoles · antimicrobial activity

Abstract

Some 2-(2-(p-chlorophenyl)benzimidazol-1-ylmethyl)-5-substituted amino-[1,3,4]-thiadiazoles were synthesized and their in vitro antimicrobial activities were tested against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Candida albicans and Candida krusei. Compounds 1b and 12b which possess remarkable activity against C. albicans and marginal activity against C. krusei were found to be the most active compounds in this series. Single crystal X-ray diffraction analysis was performed for compound 8b.

Özet

Some 2-(2-(p-chlorophenyl)benzimidazol-1-ylmethyl)-5-substituted amino-[1,3,4]-thiadiazoles were synthesized and their in vitro antimicrobial activities were tested against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Candida albicans and Candida krusei. Compounds 1b and 12b which possess remarkable activity against C. albicans and marginal activity against C. krusei were found to be the most active compounds in this series. Single crystal X-ray diffraction analysis was performed for compound 8b.

🔖

Cite This Article

KILCIGİL, G. A., KUŞ, C. (2005). Synthesis and Antimicrobial Evaluation of Some New 2-(2-(p-chlorophenyl) benzimidazol-1-yl methyl)-5-substituted amino-[1,3,4]-thiadiazoles. Turkish Journal of Chemistry, Cilt: 29 - Sayı: 2, 153–162. https://ajindex.com/articles/382202

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. A.E. Abdel-Rahman, A.M. Mahmoud, G.M. El-Naggar and H.A. El-Sherief, Pharmazie, 38, 589-590 (1983).
  2. F.S.G. Soliman, S.M. Rida, E.A.M. Badawey and T. Kappe, Arch. Pharm., 317, 951-958 (1984).
  3. R.A. Coburn, M.T. Clark, R.T. Evans and R.J. Genco, J. Med. Chem., 30, 205-208 (1987).
  4. N.S. Habib, S. Abdel-Hamid, M and El-Hawash, Farmaco, 44, 1225-1232 (1989). H. G¨oker, M. Tun¸cbilek, G. Ayhan and N. Altanlar, Farmaco, 53, 415-420 (1998).
  5. G.A. Kılcıgil, M. Tun¸cbilek, N. Altanlar and H. G¨oker, Farmaco, 54, 562-565 (1999).
  6. V.L. Khairnar, S.R. Lockhande, M.R. Patel and B.G. Khadse, Bull. Haffkine Inst. 8 (1980) 67-70: Chemical Abstract, 95, 203833h (1981).
  7. L.I. Kruse, D.L. Ladd, P.B. Harrsch, F.L. McCabe, S.M. Mong, L. Faucette and R. Johnson, J. Med. Chem., 32, 409-417(1989).
  8. I. Islam, E.B. Skibo, R.T. Dorr and D.S. Alberts, J. Med. Chem., 34, 2954-2961 (1991).
  9. V.J. Habernickel, Drugs made in Germany, 35, 97 (1992).
  10. T. Fukuda, Y. Morimoto, R. Iemura, T. Kawashima, G. Tsukamoto and K. Ito, Arzneim.-Forsch./Drug Res., 34, 801-805 (1984).
  11. T. Fukuda, T. Saito, S. Tajima, K. Shimohara and K. Ito, Arzneim.-Forsch./Drug Res., 34, 805-810 (1984).
  12. H. Nakano, T. Inoue, N. Kawasaki, H. Miyataka, H. Matsumoto, T. Taguchi, N. Inagaki, H. Nagai and T. Satoh, Chem. Pharm. Bull., 47, 1573-1578 (1999).
  13. H. Nakano, T. Inoue, N. Kawasaki, H. Miyataka, H. Matsumoto, T. Taguchi, N. Inagaki, H. Nagai and T. Satoh, Bioorg. Med. Chem., 8, 373-380 (2000).
  14. B. Can-Eke, M.O. Puskullu, E. Buyukbingol and M. Iscan, Chemico-Biological Interactions, 113, 65-77 (1998).
  15. S. Demirayak, U. Abu Mohsen and A.C. Karaburun, Eur. J. Med. Chem., 37, 255-260 (2002).
  16. S. Ersan, S. Nacak, N. Noyanalpan and E. Yesilada, Arzneim.-Forsch./Drug Res., 47, 834-836 (1997).
  17. D.H. Boschelli, D.T. Connor, D.A. Bornemeier, R.D. Dyer, J.A. Kennedy, P.J. Kuipers, G.C. Okonkwo, D.J. Schrier and C.D. Wright, J. Med. Chem., 36, 1802-1810 (1993).
  18. G. Sahin, E. Palaska, P. Kelicen, R. Demirdamar and G. Altınok, Arzneim.-Forsch./Drug Res., 51, 478-484 (2001).
  19. A. Tsotinis, A. Varvaresou, T. Calogeropoulou, T. Siatra-Papastaikoudi and A. Tiligada, Arzneim.-Forsch./Drug Res., 47, 307-310 (1997).
  20. A.C.T. North, D.C. Phillips and F.S. Mathews, Acta Cryst., A24, 351-359 (1968).
  21. G.M. Sheldrick, SHELXS97 Program for Crystal Structure Solution, University of G¨ottingen, Germany (1997).
  22. G.M. Sheldrick, SHELXL97 Program for Crystal Structure Refinement, University of G¨ottingen, Germany (1997).
  23. D.F. Sahm, J.A. Washington in Am. Soc. Microbiol.